May serum levels of advanced oxidized protein products serve as a prognostic marker of disease duration in patients with idiopathic parkinson's disease?

Antioxidants and Redox Signaling

Volumn 18, Issue 11, 2013, Pages 1296-1302

  García Moreno, José Manuel ^a,b   Martín De Pablos, Angel ^a,b   García Sánchez, María Isabel ^b   Méndez Lucena, Carolina ^a,b   Damas Hermoso, Fátima ^a,b   Rus, Macarena ^a,b   Chacón, José ^c   Fernández, Emilio ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c Hospital Infanta Luisa   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 CHLOROTYROSINE; ADVANCED OXIDATION PROTEIN PRODUCT; ALBUMIN; HYDROGEN PEROXIDE; LEVODOPA; MYELOPEROXIDASE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HALOGENATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PHAGOCYTE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW;

ADVANCED OXIDATION PROTEIN PRODUCTS; AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PARKINSON DISEASE; PROGNOSIS;

EID: 84874495729     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.5026     Document Type: Review

References (9)

1. Cardozo DL. Midbrain dopaminergic neurons from postnatal rat in long-term primary culture. Neuroscience 56: 409-421, 1993.
2. Descamps-Latscha B and Witko-Sarsat V. Importance of oxidatively modified proteins in chronic renal failure. Kidney Int 78: S108-S113, 2010.
3. Hunot S and Hirsch EC. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 53 (Suppl 3): S49-S60, 2003.
4. Kontush A and Beisiegel U. Measurement of oxidizability of blood plasma. Methods Enzymol 299: 35-49, 1999.
5. Link H and Tibbling G. Principles of albumin and IgG analyses in neurological disorders III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest 37: 397-401, 1977.
6. Mu? nch G, et al. Crosslinking of alpha-synuclein by advanced glycation endproducts - an early pathophysiological step in Lewy body formation? J Chem Neuroanat 20: 253-237, 2000.
7. Prigione A, et al. Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: negative correlation with levodopa dosage. Neurobiol Dis 23: 36-43, 2006.
8. Witko-Sarsat V, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49: 1304-1313, 1996.
9. Witko-Sarsat V, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161: 2524-2532, 1998.